Public Defence: Mariaserena Giliberto

M.Sc. Mariaserena Giliberto at Institute of Clinical Medicine will be defending the thesis “Application of drug sensitivity screening in B-cell malignancies for informing precision medicine strategies” for the degree of PhD (Philosophiae Doctor).

Image may contain: Person, Forehead, Nose, Cheek, Skin.

Photo: Per M. Didriksen, Oslo universitetssykehus HF

An electronic copy of the thesis may be ordered from the faculty up to 2 days prior to the public defence. Inquiries regarding the thesis after the public defence must be addressed to the candidate.

Trial Lecture – time and place

See Trial Lecture.

Adjudication committee

  • First opponent: Research Director Caroline Heckman, University of Helsinki, Finland
  • Second opponent: Associate Professor II Tobias Schmidt Slørdahl, Norwegian University of Sceinec Technology (NTNU)
  • Third member and chair of the evaluation committee: Professor Hilde Loge Nilsen, University of Oslo

Chair of the Defence

Professor Finn Olav Levy, University of Oslo

Principal Supervisor

Professor II, Kjetil Taskén, University of Oslo


Cancer is still in many cases an incurable disease in urgent need for effective therapies and personalized treatment protocols. The work in this Thesis presents a drug sensitivity screening approach to test a number of anti-cancer drugs directly on cancer cells from patients with blood cancer. This identified possible treatment options and indicators of drug efficacy to assist clinical decisions on future individual treatment choices. In paper I differential drug sensitivities in multiple myeloma (MM) linked to corresponding in vivo clinical responses and synergistic drug combinations were identified. In the paper II results described the therapeutic efficacy of combined MEK/Bcl-2 inhibitors and provided a biomarker-guided combinatorial approach targeting MEK and Bcl-2 in B-cell malignancies. As part of paper III results described that both mutations in cancer-related genes and activity level of signaling proteins may serve as indicators of drug sensitivity or resistance in this model. We hope that this method may provide a clinically applicable drug-testing pipeline for patients with advanced disease and few remaining treatment options.

Additional information

Contact the research support staff.

Published May 18, 2022 12:33 PM - Last modified May 31, 2022 1:52 PM